UB Paderborn / Katalog / Suche / in CDI

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014-08, Vol.10 (4), p.431

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction

Hypertension (Dallas, Tex. 1979), 2008-01, Vol.51 (1), p.48-54

2008

Link zum Volltext

Verfügbarkeit prüfen

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Journal of cardiovascular translational research, 2010-12, Vol.3 (6), p.704-716

2010

Link zum Volltext

Verfügbarkeit prüfen

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

BMC cardiovascular disorders, 2010-02, Vol.10 (1), p.7-7, Article 7

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial

The Journal of invasive cardiology, 2013-11, Vol.25 (11), p.593-599

2013

Link zum Volltext

Verfügbarkeit prüfen

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e167-e172

2018

Link zum Volltext

Verfügbarkeit prüfen

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-03, Vol.25 (2), p.189-194

2019

Link zum Volltext

Verfügbarkeit prüfen

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Journal of hypertension, 2007-09, Vol.25 (9), p.1921-1926

2007

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

FEMORAL VASCULAR CLOSURE DEVICES AND BLEEDING, HEMOSTASIS, AND AMBULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Suchergebnisse filtern